Canadian Treatment as Prevention advocate lauded by his peers

PositiveLite.com interviewee Dr. Julio Montaner has been nominated to the Canadian Medical Hall of Fame, a prestigious honour that recognizes the significant contributions and achievements by Dr. Montaner in the field of HIV/AIDS. Bob Leahy reports.

We have learned that Dr. Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS (BC-CfE), at St. Paul’s Hospital, is one of six Canadian physicians nominated to the prestigious Canadian Medical Hall of Fame for 2015.

The Canadian Medical Hall of Fame Laureates are individuals whose outstanding contributions to medicine and the health sciences have led to extraordinary improvements in human health.

PositiveLite.com has interviewed Dr. Montaner on three separate occasions in the past and supports his efforts to bring treatment as prevention strategies (TasP) to Canada and to the world. We applaud his tenacity and passion for a cause he believes in as well as his commitment to the health and wellbeing of people living with HIV. We join in congratulating him on this recognition by his peers for his longstanding contribution to the fight against HIV.

While his strategies are still controversial in parts of Canada and his personal popularity amongst policy makers is uneven, particularly in Eastern Canada, (we have always found him warn and engaging) treatment as prevention is slowly creeping into mainstream prevention efforts throughout the country, in a variety of disguises.

Word is that the patients in his Vancouver HIV practice love him.

“The Canadian Medical Hall of Fame is proud to count Dr. Julio Montaner among Canada’s illustrious medical heroes,” says Dr. Jean Gray, chair of The Canadian Medical Hall of Fame. “His contribution to health in Canada and the world is well documented and a wonderful example of the kind of passion, diligence and innovative thinking displayed by our laureates.”

Bob Leahy
PositiveLite
Read The Full Story

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below